Moderna’s Cinderella story is getting a scary rewrite on Wall Street, and a top analyst points to one path to a happy ending

During the pandemic, Moderna wrote itself a Hollywood tale of overnight riches and fame. The biotech changed the world, saved lives and prevented suffering on …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Moderna’s Cinderella story is getting a scary rewrite on Wall Street, and a top analyst points to one path to a happy ending

This article is available only to Premium subscribers

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Mod­er­na’s Cin­derel­la sto­ry is get­ting a scary rewrite on Wall Street, and a top an­a­lyst points to one path to a hap­py end­ing

This article is available only to Premium subscribers

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Biotech VC firm out­lines plans for $100M fund

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Moderna’s Cinderella story is getting a scary rewrite on Wall Street, and a top analyst points to one path to a happy ending

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development